BioNTech (NasdaqGS:BNTX) is back in focus after Arbutus Biopharma and Genevant Sciences filed new international patent lawsuits targeting the lipid nanoparticle technology used in Pfizer and BioNTech’s COVID-19 vaccines.

At a share price of $91.48, BioNTech’s short term share price returns have been relatively muted. The 1 year and 5 year total shareholder returns, down 16.85% and 67.24% respectively, point to fading longer term momentum as the patent dispute adds another layer of perceived risk.

If the legal headlines have you reassessing your biotech exposure, it could be a good moment to look at other healthcare stocks using AI. Start with this focused screener of 39 healthcare AI stocks

BioNTech now trades well below its recent highs, with sentiment weighed down by legal questions and weaker long term returns. Does the current valuation still offer a compelling balance of risk and potential reward for new money?

Most Popular Narrative: 81.7% Undervalued

BioNTech’s most followed narrative pegs fair value at $499.94 per share, far above the recent $91.48 close, which is a striking valuation gap.

"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70. Certainly not dating back to the time of AI, fusion reactors or recurring missiles.

Sahin with his strength of pattern recognition and complexity reduction would certainly have started with an IT company, like many others. It is a stroke of luck that he has decided to fight against the Geissesl of humanity, because it is clear that medicine with AI, robotics and the breakdown of human metabolism into algorithms is facing a fundamental change.

Curious what sits behind a fair value almost five times higher than BioNTech’s share price? According to Hansimglueck, the narrative leans on aggressive revenue expansion, ambitious profitability assumptions and a future earnings multiple more often associated with large tech platforms than drug developers.

Result: Fair Value of $499.94 (UNDERVALUED)

However, BioNTech’s narrative could still be knocked off course if the patent disputes intensify or key oncology and infectious disease trials deliver weaker than hoped data.

Another View on BioNTech’s Valuation

While the popular narrative flags BioNTech as heavily undervalued on a fair value of $499.94 per share, the market’s own P/S ratio of 7.2x sends a mixed signal. It sits below the US biotechs average of 11.3x, yet above both the peer average of 6.4x and the fair ratio of 5.3x.

That gap suggests investors are already paying a premium versus closer peers and the fair ratio, even though BioNTech has lagged the wider market and remains unprofitable. The key question is whether the current story justifies staying above that 5.3x level.

Next Steps

Looking for more investment ideas beyond BioNTech?

If BioNTech has sharpened your focus on risk and reward, now is a smart time to widen your search with other clear, data driven stock ideas.

• Target potential mispricing by scanning companies that currently look attractively valued using the 47 high quality undervalued stocks.
• Strengthen portfolio resilience by focusing on businesses with sturdy finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Spot underfollowed opportunities early by checking the screener containing 20 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.